Klaria Pharma’s CEO to present the company on March 12 in Stockholm

Klaria Pharma Holding AB (publ) announces that CEO Jesper Wiklund will hold a company presentation on Klaria as a part of Erik Penser Bank’s Company Day event on March 12, 2020 in Stockholm, Sweden. 

The presentation will, among other things, include Klaria’s new focused development strategy to maximize shareholder value and the pivotal clinical study for the company’s EU Horizon 2020-financed Sumatriptan Alginate Film scheduled for 2020.

There is no admission fee for attending the event, but the number of seats is limited. Registration is handled via Erik Penser Bank’s website, www.penser.se, where more information and the complete schedule for the event will be published shortly.

For more information, visit the  Klaria Pharma Holding website klaria.com or contact:
Jesper Wiklund, CEO Klaria Pharma Holding AB (publ)
investor.relations@klaria.com
Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.